blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3231428

EP3231428 - PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.01.2021
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  31.01.2020
FormerGrant of patent is intended
Status updated on  22.09.2019
FormerExamination is in progress
Status updated on  15.02.2019
FormerRequest for examination was made
Status updated on  15.09.2017
FormerThe international publication has been made
Status updated on  02.06.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Kowa Company, Ltd.
6-29, Nishiki 3-chome Naka-ku
Nagoya-shi, Aichi-ken 460-8625 / JP
[2017/42]
Inventor(s)01 / KANEKO, Yoshio
c/o KOWA COMPANY, LTD.
Tokyo New Drug Research Laboratories
2-17-43 Noguchi-cho
Higashimurayama-shi Tokyo 189-0022 / JP
02 / OHTA, Masayuki
c/o KOWA COMPANY, LTD.
Tokyo New Drug Research Laboratories
2-17-43 Noguchi-cho
Higashimurayama-shi Tokyo 189-0022 / JP
 [2017/42]
Representative(s)Schiener, Jens
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstraße 8
80333 München / DE
[2017/42]
Application number, filing date15866838.411.12.2015
[2017/42]
WO2015JP84817
Priority number, dateJP2014025205212.12.2014         Original published format: JP 2014252052
[2017/42]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016093348
Date:16.06.2016
Language:JA
[2016/24]
Type: A1 Application with search report 
No.:EP3231428
Date:18.10.2017
Language:EN
[2017/42]
Type: B1 Patent specification 
No.:EP3231428
Date:04.03.2020
Language:EN
[2020/10]
Search report(s)International search report - published on:JP16.06.2016
(Supplementary) European search report - dispatched on:EP29.06.2018
ClassificationIPC:A61K31/551, A61K31/498, A61K45/00, A61K47/22, A61P27/06, A61P43/00
[2017/42]
CPC:
A61K31/498 (EP,KR,US); A61K31/551 (EP,KR,US); A61K45/00 (EP,US);
A61K47/22 (EP,KR,US); A61P27/06 (EP,US); A61K2300/00 (KR)
C-Set:
A61K31/498, A61K2300/00 (EP,US);
A61K31/551, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ARZNEIMITTELTHERAPIE ZUR PRÄVENTION ODER BEHANDLUNG VON GLAUKOMEN[2017/42]
English:PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA[2017/42]
French:PHARMACOTHÉRAPIE POUR LA PRÉVENTION OU LE TRAITEMENT DU GLAUCOME[2017/42]
Entry into regional phase02.06.2017Translation filed 
02.06.2017National basic fee paid 
02.06.2017Search fee paid 
02.06.2017Designation fee(s) paid 
02.06.2017Examination fee paid 
Examination procedure02.06.2017Examination requested  [2017/42]
02.06.2017Date on which the examining division has become responsible
15.01.2019Amendment by applicant (claims and/or description)
19.02.2019Despatch of a communication from the examining division (Time limit: M04)
18.06.2019Reply to a communication from the examining division
23.09.2019Communication of intention to grant the patent
23.01.2020Fee for grant paid
23.01.2020Fee for publishing/printing paid
23.01.2020Receipt of the translation of the claim(s)
Opposition(s)07.12.2020No opposition filed within time limit [2021/06]
Fees paidRenewal fee
01.01.2018Renewal fee patent year 03
21.12.2018Renewal fee patent year 04
31.12.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.12.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MK04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
[2022/31]
Former [2022/30]HU11.12.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2022/27]HU11.12.2015
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/40]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/10]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/08]CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/50]CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/49]CZ04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/48]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/47]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/46]FI04.03.2020
HR04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/45]FI04.03.2020
HR04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
Former [2020/39]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
Former [2020/38]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
NO04.06.2020
GR05.06.2020
Former [2020/37]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
NO04.06.2020
Former [2020/35]FI04.03.2020
NO04.06.2020
Documents cited:Search[Y]EP1818059  (KOWA CO [JP]) [Y] 1-11 * page 2, paragraph [0001] * * page 3, paragraph [0023] * * page 5, paragraph [0045] * * page 6, paragraph [0050] * * claims 1, 2 *;
 [Y]US2011178145  (DONELLO JOHN E [US], et al) [Y] 1-11 * page 1, paragraphs [0002]-[0006] *;
 [E]EP3231429  (KOWA CO [JP]) [E] 1-11 * page 3, paragraph [0007] ** claims 1-4, 7 *;
 [XDI]  - TADASHIRO SAEKI ET AL, "Mouse Gan'atsu ni Taisuru ROCK Sogaizai K115 to Brimonidine no Heiyo Koka [Effect of combination of ROCK inhibitor K 15 and brimonidine on mouse intraocular pressure]", JAPANESE SOCIETY FOR OCULAR PHARMACOLOGY PROGRAM.KEEN SHOROKUSHU, JAPANESE SOCIETY FOR OCULAR PHARMACOLOGY, JP, (20070101), vol. 27, page 59, XP009503706 [XD] 1-8,10,11 * the whole document * [I] 9
 [I]  - LEE ANNE J ET AL, "Emerging drugs for ocular hypertension", EXPERT OPINION ON EMERGING DRUGS ENG, INFORMA HEALTHCARE, UK, (20110301), vol. 16, no. 1, doi:10.1517/14728214.2011.521631, ISSN 1744-7623, pages 137 - 161, XP008161576 [I] 1-11 * abstract * * page 140; table 1 * * page 142, column 1, paragraph 3 - column 2, paragraph 1 * * page 148, column 2, paragraph 5 * * page 149; table 3 *

DOI:   http://dx.doi.org/10.1517/14728214.2011.521631
International search[YA]WO2006068208  (KOWA CO [JP], et al) [Y] 3, 7, 9 * , entire text & JP 4099201 B & US 2006/0142270 A1 & EP 1818059 A1 * [A] 1, 2, 4-6, 8, 10-13;
 [YA]JP2012250953  (SANTEN PHARMA CO LTD) [Y] 3, 7, 9 * , examples (Family: none) * [A] 1, 2, 4-6, 8, 10-13;
 [YA]JP2014520895  (Allergan, Inc.) [Y] 3, 7, 9 * , examples & WO 2013/013143 A1 examples & US 2014/0249153 A1 & EP 2734206 A1 * [A] 1, 2, 4-6, 8, 10-13;
 [XY]  - TADASHIRO SAEKI et al., "Mouse Gan'atsu ni Taisuru ROCK Sogaizai K115 to Brimonidine no Heiyo Koka", Japanese Society for Ocular Pharmacology Program·Keen Shorokushu, (20070000), vol. 27, page 59, XP009503706 [X] 1, 2, 4-6, 8, 10-13 [Y] 3, 7, 9
 [A]  - GOMI NORIAKI et al., "A Practical Synthesis of (S)-tert-Butyl-3-Methyl-1,4-diazepane-1- carboxylate, the Key Intermediate of Rho-Kinase Inhibitor K-115", Synthesis, (20120000), vol. 44, no. 20, pages 3171 - 3178, XP 055453983 [A] 1-13 * (A document showing the structure of K115) *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.